Intriguingly, in CRC, SIRT3 displays an oncogenic role by deacetylating SHMT2 [27], and acts as tumor suppressor by increasing ROS production and PINK1/Parkin/mitophagy axis activation [9]. Here, SHMT2 is linked to neoplasm.